{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:30:43Z","timestamp":1792517443398,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Eosinophilia is associated with a wide variety of allergic, rheumatologic, infectious, neoplastic, and rare idiopathic disorders. Clinical manifestations range from benign asymptomatic presentations to life-threatening complications, including endomyocardial fibrosis and thromboembolism. The prognosis and choice of treatment depend not only on the degree of eosinophilia and severity of organ involvement, but also on the etiology of the eosinophilia. Unfortunately, despite recent advances in molecular and immunologic techniques, the etiology remains unproven in the overwhelming majority of cases. This review presents a practical approach to the diagnosis and treatment of patients presenting with unexplained marked eosinophilia. A brief overview of the mechanisms of eosinophilia and eosinophil pathogenesis is also provided.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.92","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T11:23:25Z","timestamp":1473938605000},"page":"92-97","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":59,"title":["Eosinophilia: a pragmatic approach to diagnosis and treatment"],"prefix":"10.1182","volume":"2015","author":[{"given":"Amy D.","family":"Klion","sequence":"first","affiliation":[{"name":"Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2019111703002262000_B1","doi-asserted-by":"crossref","first-page":"F43","DOI":"10.1084\/jem.20020636","article-title":"Making eosinophils through subtle shifts in transcription factor expression","volume":"195","author":"McNagny","year":"2002","journal-title":"J Exp Med"},{"issue":"6","key":"2019111703002262000_B2","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.V73.6.1504.1504","article-title":"Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF","volume":"73","author":"Clutterbuck","year":"1989","journal-title":"Blood"},{"issue":"8","key":"2019111703002262000_B3","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.4049\/jimmunol.1400732","article-title":"IL-5 triggers a cooperative cytokine network that promotes eosinophil precursor maturation","volume":"193","author":"Fulkerson","year":"2014","journal-title":"J Immunol"},{"issue":"7470","key":"2019111703002262000_B4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nature12526","article-title":"Type 2 innate lymphoid cells control eosinophil homeostasis","volume":"502","author":"Nussbaum","year":"2013","journal-title":"Nature"},{"issue":"1","key":"2019111703002262000_B5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1084\/jem.20081756","article-title":"Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor","volume":"206","author":"Mori","year":"2009","journal-title":"J Exp Med"},{"issue":"1","key":"2019111703002262000_B6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ni.2757","article-title":"Paired immunoglobulin-like receptor A is an intrinsic, self-limited suppressor of IL-5 induced eosinophil development","volume":"15","author":"Ben Baruch-Morgenstern","year":"2014","journal-title":"Nat Immunol"},{"issue":"3","key":"2019111703002262000_B7","doi-asserted-by":"crossref","first-page":"e59397","DOI":"10.1371\/journal.pone.0059397","article-title":"Targeted ablation of miR-21 decreases murine eosinophil progenitor cell growth","volume":"8","author":"Lu","year":"2013","journal-title":"PloS One"},{"key":"2019111703002262000_B8","first-page":"121","article-title":"Eosinophils in health and disease","volume-title":"Eosinophil Trafficking","author":"Lee","year":"2013"},{"issue":"25","key":"2019111703002262000_B9","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2014-10-607788","article-title":"Eosinophil-specific deletion of I\u03baB\u03b1 in mice reveals a critical role of NF-\u03baB\u2013induced Bcl-xL for inhibition of apoptosis","volume":"125","author":"Schwartz","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111703002262000_B10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jaci.2015.01.004","article-title":"Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells","volume":"135","author":"Jia","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"1-2","key":"2019111703002262000_B11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000357004","article-title":"Remodeling and fibrosis in chronic eosinophil inflammation","volume":"32","author":"Aceves","year":"2014","journal-title":"Dig Dis"},{"issue":"2","key":"2019111703002262000_B12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2005-05-2152","article-title":"The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states","volume":"107","author":"Wang","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111703002262000_B13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nrrheum.2014.98","article-title":"Eosinophils in vasculitis: characteristics and roles in pathogenesis","volume":"10","author":"Khoury","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"2019111703002262000_B14","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood-2012-05-432088","article-title":"Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion competent eosinophil granules in humans","volume":"121","author":"Ueki","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111703002262000_B15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nm.1855","article-title":"Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense","volume":"14","author":"Yousefi","year":"2008","journal-title":"Nat Med"},{"issue":"5","key":"2019111703002262000_B16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1189\/jlb.3RU0214-110R","article-title":"Unraveling the complexity of lipid body organelles in human eosinophils","volume":"96","author":"Melo","year":"2014","journal-title":"J Leuk Biol"},{"key":"2019111703002262000_B17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/bs.ai.2014.09.002","article-title":"Mast cells' integrated actions with eosinophils and fibroblasts in allergic inflammation: implications for therapy","volume":"125","author":"Landolina","year":"2015","journal-title":"Adv Immunol"},{"key":"2019111703002262000_B18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2014.00496","article-title":"Eosinophil secretion of granule-derived cytokines","volume":"5","author":"Spencer","year":"2014","journal-title":"Front Immunol"},{"issue":"6","key":"2019111703002262000_B19","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.7326\/0003-4819-68-6-1220","article-title":"The hypereosinophilic syndromes","volume":"68","author":"Hardy","year":"1968","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019111703002262000_B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of 14 cases with review of the literature","volume":"54","author":"Chusid","year":"1984","journal-title":"Medicine"},{"issue":"6","key":"2019111703002262000_B21","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2019111703002262000_B22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"2019111703002262000_B23","volume-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissue","author":"Swerdlow","year":"2008"},{"issue":"1","key":"2019111703002262000_B24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaci.2010.03.042","article-title":"Refining the definition of hypereosinophilic syndrome","volume":"126","author":"Simon","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2019111703002262000_B25","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111703002262000_B26","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2013.06.037","article-title":"Marked and persistent eosinophilia in the absence of clinical manifestations","volume":"133","author":"Chen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"2019111703002262000_B27","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.cgh.2006.08.013","article-title":"Potential of blood eosinophils, eosinophil-derived neurotoxin and eotaxin-3 as biomarkers of eosinophilic esophagitis","volume":"4","author":"Konikoff","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2019111703002262000_B28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12032-013-0815-1","article-title":"Characteristics and clinical outcome of patients with hypereosinophilia of undeteremined significance","volume":"31","author":"Helbig","year":"2014","journal-title":"Med Oncol"},{"key":"2019111703002262000_B29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1146\/annurev-pharmtox-010814-124407","article-title":"Novel targeted therapies for eosinophil-associated diseases and allergy","volume":"55","author":"Radonjic-Hoesli","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"13","key":"2019111703002262000_B30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutoc target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111703002262000_B31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"9","key":"2019111703002262000_B32","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2003-07-2393","article-title":"Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes","volume":"102","author":"Pitini","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2019111703002262000_B33","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1398-9995.2009.01943.x","article-title":"A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia\/hypereosinophilic syndrome","volume":"64","author":"Salemi","year":"2009","journal-title":"Allergy"},{"issue":"4","key":"2019111703002262000_B34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2013.12.007","article-title":"Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA","volume":"42","author":"Sadovnik","year":"2014","journal-title":"Exp Hematol"},{"issue":"15","key":"2019111703002262000_B35","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","author":"Simon","year":"1999","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111703002262000_B36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MD.0000000000000088","article-title":"The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype","volume":"93","author":"Lef\u00e8vre","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"2019111703002262000_B37","first-page":"753","article-title":"6q\u2212 is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome","volume":"90","author":"Ravoet","year":"2005","journal-title":"Haematologica"},{"issue":"12","key":"2019111703002262000_B38","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111703002262000_B39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2019111703002262000_B40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrd3838","article-title":"Targeting eosinophils in allergy, inflammation and beyond","volume":"12","author":"Fulkerson","year":"2013","journal-title":"Nat Rev Drug Discov"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/92\/1251501\/bep00115000092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/92\/1251501\/bep00115000092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:00:56Z","timestamp":1573959656000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/92\/20764\/Eosinophilia-a-pragmatic-approach-to-diagnosis-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.92","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}